Consumer Defensive · Beverages - Alcoholic · Synthos Deep Dive · 2026-07-03
| Verdict | Avoid — systematic Synthos tier |
| Price (2026-07-02) | $137.47 · market cap ~$23.5B |
| Synthos scores (0–10) | Downside Risk 6 · Growth Quality 3 · Exponential Potential 2 |
| Synthos fair value (base case) | ~$160 → +16% · full range $113 (bear) – $200 (bull) |
| Street consensus | $169 (high $197 / low $139; 25 Buy · 20 Hold · 1 Sell) — context, not our anchor |
| Valuation | 13× trailing EPS · ~12× FY27E comparable · 11× FY29E · EV/S 3.7× · EV/EBITDA 10.7× · FCF yield ~7.8% |
| Exponential Potential | 2/10 · Low — single-category beer maturing, depletions turning negative, wine/spirits divested; ~6% forward EPS CAGR is mostly buyback |
| Technicals | Downtrend — $137, −22% off 52-wk high, below 50/200-DMA, RSI 41, −17% 12-mo (SPY +21%) |
| Conviction | Low — 0 net-bullish voices, 0 traceable claims; the call rests on quant + fundamentals only |
| Position sizing | If owned, income/value satellite ~1–2% — not a core holding at current momentum |
| Next catalyst | 2026-10-01 Q2 FY27 earnings (Street EPS $3.61) |
| Single biggest risk | US tariffs on Mexican imports + a softening core-consumer (Hispanic) beer demand — both hit the ~91% beer engine directly |
One-line thesis. Constellation is a cheap, cash-generative beer company (Modelo, Corona, Pacifico) trading at 13× earnings with a ~3% dividend — but revenue fell 10% in FY26, beer depletions have turned negative, management itself guides to roughly flat organic sales, and 100% of the beer it sells is brewed in Mexico into a US tariff regime. Cheap for reasons; a Watch, not yet a Buy.
Constellation is the company behind Modelo, Corona, and Pacifico beer in the United States — it owns the US rights to those Mexican beer brands, and beer is now roughly 91% of the whole business (it recently sold off most of its wine and spirits). It also still owns wine labels like Kim Crawford and The Prisoner.
Is the stock cheap or expensive? Cheap — you pay about $13 for every $1 of annual profit, versus $20–$25 for a typical big consumer brand, and it pays a ~3% dividend. But it's cheap for a reason: sales are shrinking, not growing, and the beer it sells is all made in Mexico, so new US tariffs on Mexican goods raise its costs and the news keeps hanging over the stock. The stock is down about 17% over the past year while the market rose 21%.
Our verdict is Watch — not a buy, not a sell. It's a fair price for a wobbling business; we'd want to see the sales decline stop before calling it a buy.
Here's what our three scores mean in everyday terms:
The one big worry: US tariffs on Mexican imports plus a softer core beer consumer. Every bottle Constellation sells in the US is brewed in Mexico, so both hit the part of the company that matters most.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 41.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = STZ · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Constellation Brands (NYSE: STZ) is a Rochester, NY beverage company founded in 1945. After the 2025 divestiture of most of its wine & spirits portfolio, it is now overwhelmingly a US beer business built on the American rights to a set of Mexican import brands — Modelo Especial, Corona Extra/Familiar, Pacifico, Victoria, and the Modelo Chelada line. A residual, higher-end Wine & Spirits unit remains (The Prisoner, Robert Mondavi, Kim Crawford, Mi CAMPO Tequila, High West). Fiscal year ends the last day of February; the most recent reported quarter is Q1 FY2027 (ended 2026-05-31).
Revenue mix (FY2026, from filings):
The strategic reality: Constellation bet its future on premium Mexican beer in the US, and that bet drove a decade of share gains. The question now is whether that engine has matured just as its core consumer softens and trade policy turns against Mexican imports.
There is no expert coverage of STZ in the Synthos knowledge base: total_claims = 0, 0 net-bullish voices, 0 traceable claims. We will not manufacture conviction we do not have. Nothing in this note cites a claim_id, because none exist for this name.
That means the verdict below is fundamentals- and quant-driven: reported financials, live analyst estimates (FMP), management's own guidance (§9, half-weighted), the price-target consensus (as context only), and our own scenario model. Where the Street is bullish (25 Buy ratings, $169 median target), we treat that as one input, not our anchor — and we land more cautiously than the sell side because the top-line and trade-policy risks are, in our read, under-weighted at a Buy consensus.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Cheap (13× P/E) and low-beta (0.38) cushion the downside, but net-debt/EBITDA 3.3×, a −50% max drawdown, negative price trend, and a structural Mexican-import/tariff exposure raise it. |
| Growth Quality | 3 · Poor | Revenue −10% in FY26; beer depletions turned negative (Modelo −2%, Corona −5% in Q1 FY27); comparable EPS guided flat-to-down; the ~6% forward EPS CAGR is largely buyback-driven, not volume. |
| Exponential Potential | 2 · Low | A mature single-category beer business in a maturing US alcohol market; wine/spirits divested; no accelerating leg. This is a value/income name, not a compounder. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. EPS below refers to comparable (adjusted) EPS, the metric management and the Street anchor on; FY26 comparable EPS was $11.82.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Depletions stabilize, tariffs prove manageable/pass-through, buybacks shrink the share count; FY27E comparable EPS lands top-of-guide ~$12.5 and the multiple re-rates back toward a staple ~16×. | ~$200 (+45%) |
| Base (our anchor) | Guidance roughly holds — organic sales ~flat, comparable EPS ~$11.85 (mid-guide/consensus); a low-growth, levered, tariff-exposed staple earns a ~13.5× multiple. | ~$160 (+16%) |
| Bear | Tariffs bite margins, Hispanic-consumer/beer demand keeps softening, depletions stay negative; comparable EPS slips to ~$10.8 and the multiple de-rates to ~10.5×. | ~$113 (−18%) |
Synthos fair value = the base case, ~$160 (+16%), with the full $113–$200 span as the honest range. Our base sits below the Street's $169 median because we give more weight to the top-line decline and tariff overhang. Note the base case's +16% is real, but it is entirely a valuation re-rate off a cheap multiple — there is little-to-no earnings growth doing the work, which is exactly why the verdict is Watch, not Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). STZ is neither right now — it is a mature cash cow in mild decline:
Exponential Potential: Low (2/10). Own STZ, if at all, for value + a ~3% dividend + buyback-driven EPS, never for a multibagger. A small, accelerating beverage name would score far higher; STZ scores low precisely because it is large, single-category, and decelerating.
STZ is statistically cheap: 13.1× trailing GAAP EPS, ~12× FY27E comparable EPS, 10.7× EV/EBITDA, 3.7× EV/sales, and a ~7.8% free-cash-flow yield with a ~3.0% dividend. On a PEG-style read the multiple is low even against modest growth. The bull case is simply: a durable, high-margin beer franchise should not trade at a market-discount multiple.
The bear rebuttal — and why we don't just call it a Buy — is that the cheapness is the market pricing three real problems: (1) revenue is declining, not growing; (2) ~100% of beer COGS is Mexican-sourced into a US tariff regime; (3) leverage is 3.3×. Cheap staples with shrinking volumes and a policy overhang can stay cheap or get cheaper (a value trap). Street targets (context): consensus/median ~$169–$174, high $197, low $139 — the sell side effectively assumes a re-rate and stabilization. Our base $160 credits the re-rate but not a growth inflection, so it lands below consensus. Not a value trap on our numbers, but not a table-pounding value buy either — a Watch.
Constellation's moat is narrow but real: perpetual US brand rights to Modelo, Corona, and Pacifico, iconic import brands with genuine pricing power (Modelo Especial is the #1 US beer by dollar sales, and STZ was the #1 dollar-share gainer in Circana US tracked channels in Q1 FY27). High beer operating margins (~39%) and strong distributor relationships are durable. The limits of the moat: it is a single-category, single-geography-of-supply franchise; the US beer category is mature and volume-declining; and the core consumer skews to a Hispanic demographic whose spending has softened. The wine/spirits arm has negative competitive standing — hence the divestitures and impairments.
Peer set (market cap): Brown-Forman $12.2B (the closest pure alcohol comp), FEMSA $44.1B, Coca-Cola FEMSA $22.6B, Church & Dwight $23.4B, General Mills $20.1B, Tyson $21.0B, Bunge $20.7B, Dollar General $26.1B, Dollar Tree $23.8B. Within staples STZ has better margins than most food peers but worse growth and higher leverage than the beverage majors — the classic "high-quality asset, low-quality moment" profile.
- Comparable EPS $11.20 – $11.90 (vs FY26 comparable $11.82) and reported EPS $11.50 – $12.20 (vs FY26 reported $9.61) — i.e. essentially flat comparable earnings.
- Enterprise organic net sales −1% to +1%; beer −1% to +1%; wine & spirits organic −1% to +1%. Explicitly guiding to no growth.
- Enterprise operating margin 32–33%; beer 37–38%.
- Operating cash flow $2.4–$2.5B, capex ~$800M, free cash flow $1.6–$1.7B.
- Reaffirmed the ~3.0× target net leverage and dividend ($1.03/qtr Class A).
This is a credible, self-consistent release (revenue, segment detail, explicit FY27 outlook) — and notably, management is guiding to flat sales and flat comparable EPS itself. That candor is a point in its favor, but it is also confirmation that the growth engine has stalled. Half-weighted, it supports our Base case, not the bull.
Thesis tripwires (what would change the call): Upgrade to Buy if depletions turn positive for two quarters AND tariff risk clears, with the stock basing above its 200-DMA. Downgrade to Avoid if a tariff step-up compresses beer margin below ~35%, or depletions accelerate downward and leverage drifts above ~3.5×.
Watch. Constellation is a cheap (13× earnings, ~7.8% FCF yield, ~3% dividend), high-margin beer franchise — but it is shrinking, not growing: FY26 revenue −10%, beer depletions negative, management itself guiding FY27 to flat organic sales and flat comparable EPS, all while carrying 3.3× leverage and a Mexican-import/tariff overhang and trading in a clear downtrend (−17% 12-mo, −50% from its peak). The valuation gives a real ~+16% base-case re-rate, but that upside is purely multiple, not earnings — not enough, against these headwinds and a downtrending chart, to clear a Buy bar. There is no expert coverage to add conviction either way.
claim_id is cited anywhere in this note. The verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here we simply have none to reconcile.